Zydus Therapeutics Inc.
Clinical trials sponsored by Zydus Therapeutics Inc., explained in plain language.
-
Fatty liver drug trial in HIV patients halted early
Disease control TerminatedThis study tested a drug called saroglitazar magnesium for nonalcoholic fatty liver disease (NAFLD) in people with HIV. The goal was to see if it could reduce liver fat. However, the trial was stopped early and only enrolled 4 participants, so no conclusions can be drawn.
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
Fatty liver drug trial in PCOS women halted early
Disease control TerminatedThis study tested a drug called saroglitazar in women with polycystic ovary syndrome (PCOS) who also had nonalcoholic fatty liver disease (NAFLD). The goal was to see if the drug could reduce liver fat over 24 weeks. The trial was stopped early, so results are limited. It involve…
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Apr 26, 2026 20:03 UTC